Research And Early Development At Roche, A Work In Progress: An Interview With Mike Burgess
The acting head of Roche pharma research and early development stepped into the job amid major personnel changes in the pharma organization and the consolidation and streamlining of pRED. He spoke with the “The Pink Sheet” about his group’s priorities and the inevitable short-term hit to research productivity.
You may also be interested in...
Oncology may consume a disproportionate percentage of Roche’s R&D budget and generate the bulk of its revenues, but at a day-long symposium celebrating the opening of Roche’s new translational research center in NYC, the company’s scientific leaders highlighted its priorities in other complex diseases.
Amid a day of celebrations around the long-awaited opening of its translational and clinical research center in New York, Roche’s new head of research and early development, the superstar scientist John Reed, offered a glimpse of how the organization is restructuring its external relationships and its priorities going forward.
In the first half of 2013, two drugs for serious, ultra-rare diseases will have launched in the U.S. priced at $250,000 annually. One is encountering minimal resistance among payers; the other is expected to face a hard road. Plus a look at Celgene/Forma, Bayer/Conceptus, Soligenix/Intrexon; Regeneron/Sanofi and more.